Treatments for asthma, chronic rhinosinusitis with nasal polyps, dyslipidemia, Cushing syndrome, gonorrhea, HSCT-associated thrombotic microangiopathy, marginal zone lymphoma, motion sickness, ...

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

Investing.com -- Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 8% after the U.S. Food and Drug Administration (FDA) approved the company’s Linzess (linaclotide) capsules for pediatric patients 7 ...

The FDA announced that it will relax certain rules for approving low-cost versions of some high-priced medications.

Lifileucel shows a 25.6% objective response rate and 71.8% disease control rate in advanced nonsquamous NSCLC patients, ...

The FDA plans to eliminate comparative clinical study requirements that currently add $24 million and up to eight years to ...

Biohaven stock cratered Wednesday after the FDA rejected the company's treatment for an inherited neurodegenerative disease.

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

The Food and Drug Administration awarded the drug’s sponsor, biotech company Revolution Medicines, a new and unconventional ...

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive treatments—such as monoclonal antibodies—sooner.

The FDA has approved Transcranial Magnetic Stimulation (TMS), a non-drug, magnetic pulse device, for use in teens as young as ...

Is Galleri the future of cancer treatment? It's not that simple. The new research from the company, while promising, isn't ...